An interventional study of non surgical and surgical periodontal therapy in Periodontitis, sponsored by Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre. Completed at 1 site in India. Open to participants aged 30 Years to 50 Years. Per ClinicalTrials.gov, last updated 2018-08-21.
Sponsored by Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre · Not applicable, Interventional, and Screening
Reviewed literature suggests that sclerostin will inhibit the bone formation and ultimately leads to chronic periodontitis. Estimation of Sclerostin levels in the serum of periodontitis patients before and after intervention could explore the effectiveness of therapy and also give a more detailed insight into its diagnostic and prognostic potential as a biomarker of periodontal disease.
Advances during the last decade provided relevant information on the regulation of Sost/sclerostin and its mechanism(s) of action. Several stimuli have been reported to regulate Sost/Sclerostin expression, however how these factors interplay to regulate the expression of this gene in a spatiotemporal manner is unknown. Animal studies demonstrate that sclerostin is key for skeletal homeostasis, and required for the bone anabolic response to mechanical loading although appears dispensable for PTH-induced bone gain. The knowledge provided by preclinical investigations resulted in clinical trials based on the neutralization of sclerostin activity as a novel osteoanabolic therapeutic approach. It is now clear that sclerostin is capable of uncoupling bone formation and bone resorption, by inhibiting osteoblast function while stimulating osteoclast function, as the bone gain achieved by pharmacologic inhibition of sclerostin results from stimulation of osteoblast activity and inhibition of bone resorption. Furthermore, the recent observations show that activation of βcatenin in osteocytes increases bone resorption and Rankl production in a sclerostin-dependent manner. Anti-sclerostin therapy has shown beneficial skeletal outcomes in osteoporotic patients, however more recent evidence shows that the anabolic effects of this therapy attenuate with time and that after discontinuation BMD returns to pretreatment levels over time. The new evidence showing increased levels of Sost/sclerostin (and Dkk1) after activation of Wnt-βcatenin signaling suggest that sclerostin (and Dkk1) act as a negative feedback limiting bone formation stimulated by this pathway.
In this study is there any alterations in sclerostin levels in serum response to periodontal therapy was checked. Periodontal therapy alters the inflammation pathway is a proven fact.
1,635 studies on the registry are indexed under Periodontitis; 327 are open to participants now.
This study's enrollment of 30 is below the median of 45 across 1,191 interventional studies indexed under Periodontitis.
Browse Periodontitis studies →Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre is the lead sponsor of 25 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:• Systemically healthy individuals with more than 50% remaining natural teeth
Exclusion Criteria:• The patients who have aggressive periodontitis/localized periodontitis
nonsurgical periodontal therapy(scaling and root planing) surgical therapy( flap surgery)
Other: non surgical and surgical periodontal therapy
scaling and root planing periodontal flap surgery
sclerostin level response to only scaling and root planing
measuring serum sclerostin levels in pg/ml(Pico grams per milli liter),
Time frame: 4 weeks
sclerostin level response to periodontal surgery
measuring serum sclerostin levels after surgery in pg/ml(Pico grams per milli liter)
Time frame: 6 weeks
periodontal parametors
pocket probing depth,Clinical Attachment Level(CAL), both are in mm
Time frame: 0-4-6 weeks
Plan to share: No
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre